Grady Memorial Hospital, Atlanta, GA 30303, USA.
Diagn Microbiol Infect Dis. 2010 Sep;68(1):73-9. doi: 10.1016/j.diagmicrobio.2010.04.002.
The Tigecycline Evaluation and Surveillance Trial is a global surveillance study established in 2004 to monitor the activity of tigecycline, a new glycylcycline, and several comparators against an array of important Gram-positive and Gram-negative pathogens. In this study, we examined 1591 isolates of Acinetobacter from blood samples collected from 352 centers globally between 2004 and 2008. Tigecycline showed an MIC(90) (1 microg/mL) globally, with a maximum regional value of 4 microg/mL (Middle East) reported. Antimicrobial susceptibility was notably higher among nonintensive care unit (non-ICU) isolates than isolates collected from ICUs. Carbapenem-resistant Acinetobacter were more prevalent in the Middle East, Latin America, and Asia/Pacific rim than in Europe or North America. Tigecycline creep was noted between 2004 and 2007, corresponding closely to changes in MIC(90).
替加环素评估和监测试验是一项全球性监测研究，成立于 2004 年，旨在监测新型甘氨酰环素替加环素的活性，以及几种对照药物对一系列重要革兰阳性和革兰阴性病原体的作用。在这项研究中，我们检查了 2004 年至 2008 年间从全球 352 个中心采集的血样中的 1591 株不动杆菌分离株。替加环素在全球范围内的 MIC90（1μg/ml），报告的最高地区值为 4μg/ml（中东）。非重症监护病房（非 ICU）分离株的抗菌药物敏感性明显高于 ICU 分离株。耐碳青霉烯类不动杆菌在中东、拉丁美洲和亚太地区/环太平洋地区比在欧洲或北美更为普遍。替加环素的耐药性在 2004 年至 2007 年间逐渐增加，与 MIC90 的变化密切相关。
